HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Jensen, Richard A ^a   Agardh, Elisabet ^b   Lernmark, Åke ^c,d   Gudbjörnsdottir, Soffia ^e   Smith, Nicholas L ^a,f,g   Siscovick, David S ^a,c   Törn, Carina ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF WASHINGTON   (United States)

^d LUND UNIVERSITY   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; HLA A2 ANTIGEN; HLA ANTIGEN; HLA DQ ANTIGEN; HLA DQ2 ANTIGEN; HLA DQ6 ANTIGEN; HLA DQ8 ANTIGEN; INSULINOMA ANTIGEN 2 ANTIBODY; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; EYE FUNDUS; EYE PHOTOGRAPHY; FEMALE; GENETIC ASSOCIATION; HAPLOTYPE; HLA SYSTEM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULINOMA; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; GENETICS; GENOTYPE; IMMUNOLOGY; PANCREAS ISLET; REGRESSION ANALYSIS; SWEDEN;

ADOLESCENT; ADULT; AUTOANTIBODIES; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; FEMALE; GENOTYPE; HLA ANTIGENS; HUMANS; ISLETS OF LANGERHANS; MALE; REGRESSION ANALYSIS; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 79952611791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017569     Document Type: Article

References (83)

1. (2008) Diabetes. Fact sheet Number 312: World Health Organization.
2. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
3. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853.
4. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, et al. (2007) Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 30: 1995-1997.
5. Zhang L, Krzentowski G, Albert A, Lefebvre PJ, (2001) Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 24: 1275-1279.
6. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, et al. (2001) Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 44: 290-297.
7. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, et al. (1996) Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 39: 807-812.
8. Ziegler AG, Hillebrand B, Rabl W, Mayrhofer M, Hummel M, et al. (1993) On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 36: 402-408.
9. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, et al. (1994) Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43: 1304-1310.
10. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, et al. (1990) Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: 147-149.
11. Bottazzo GF, Florin-Christensen A, Doniach D, (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279-1283.
12. Lernmark A, Freedman ZR, Hofmann C, Rubenstein AH, Steiner DF, et al. (1978) Islet-cell-surface antibodies in juvenile diabetes mellitus. N Engl J Med 299: 375-380.
13. MacCuish AC, Irvine WJ, Barnes EW, Duncan LJ, (1974) Antibodies to pancreatic islet cells in insulin-dependent diabetics with coexistent autoimmune disease. Lancet 2: 1529-1531.
14. Karlsen AE, Hagopian WA, Grubin CE, Dube S, Disteche CM, et al. (1991) Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci U S A 88: 8337-8341.
15. Karlsen AE, Hagopian WA, Petersen JS, Boel E, Dyrberg T, et al. (1992) Recombinant glutamic acid decarboxylase (representing the single isoform expressed in human islets) detects IDDM-associated 64,000-M(r) autoantibodies. Diabetes 41: 1355-1359.
16. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, et al. (1990) Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151-156.
17. Lan MS, Lu J, Goto Y, Notkins AL, (1994) Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 13: 505-514.
18. Payton MA, Hawkes CJ, Christie MR, (1995) Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96: 1506-1511.
19. Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, et al. (1994) Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152: 3183-3188.
20. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, et al. (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222: 1337-1339.
21. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, et al. (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104: 17040-17045.
22. Rolandsson O, Hagg E, Janer M, Rutledge E, Gaur LK, et al. (2003) High GAD65 autoantibody levels in nondiabetic adults are associated with HLA but not with CTLA-4 or INS VNTR. J Intern Med 253: 447-453.
23. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, et al. (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89: 3896-3902.
24. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, et al. (2002) Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51: 1346-1355.
25. Schenker M, Hummel M, Ferber K, Walter M, Keller E, et al. (1999) Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIAB study. Diabetologia 42: 671-677.
26. Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, et al. (1995) HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 44: 608-613.
27. Sherry NA, Tsai EB, Herold KC, (2005) Natural history of beta-cell function in type 1 diabetes. Diabetes 54 (Suppl 2): S32-39.
28. Jensen RA, Gilliam LK, Torn C, Landin-Olsson M, Karlsson FA, et al. (2007) Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Complications 21: 205-213.
29. Agardh E, Gaur LK, Lernmark A, Agardh CD, (2004) HLA-DRB1,-DQA1, and-DQB1 subtypes or ACE gene polymorphisms do not seem to be risk markers for severe retinopathy in younger Type 1 diabetic patients. J Diabetes Complications 18: 32-36.
30. Becker B, Shin DH, Burgess D, Kilo C, Miller WV, (1977) Histocompatibility antigens and diabetic retinopathy. Diabetes 26: 997-999.
31. Groop LC, Teir H, Koskimies S, Groop PH, Matikainen E, et al. (1986) Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes. Diabetes 35: 1397-1403.
32. Hawrami K, Mohan R, Mohan V, Hitman GA, (1991) A genetic study of retinopathy in south Indian type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 441-444.
33. Middleton D, Johnston PB, Gillespie EL, (1985) HLA-DR antigen association with proliferative diabetic retinopathy. Int Ophthalmol 8: 33-35.
34. Mimura T, Amano S, Kato S, Araie M, Funatsu H, et al. (2004) HLA typing is not predictive of proliferative diabetic retinopathy in patients with younger onset type 2 diabetes mellitus. Br J Ophthalmol 88: 303-305.
35. Weber B, Burger W, Hartmann R, Hovener G, Malchus R, et al. (1986) Risk factors for the development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 29: 23-29.
36. Wong TY, Cruickshank KJ, Klein R, Klein BE, Moss SE, et al. (2002) HLA-DR3 and DR4 and their relation to the incidence and progression of diabetic retinopathy. Ophthalmology 109: 275-281.
37. Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh CD, et al. (1996) HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM. Diabetologia 39: 1313-1317.
38. Baker RS, Rand LI, Krolewski AS, Maki T, Warram JH, et al. (1986) Influence of HLA-DR phenotype and myopia on the risk of nonproliferative and proliferative diabetic retinopathy. Am J Ophthalmol 102: 693-700.
39. Birinci A, Birinci H, Abidinoglu R, Durupinar B, Oge I, (2002) Diabetic retinopathy and HLA antigens in type 2 diabetes mellitus. Eur J Ophthalmol 12: 89-93.
40. Dornan TL, Ting A, McPherson CK, Peckar CO, Mann JI, et al. (1982) Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics. Diabetes 31: 226-231.
41. Falck AA, Knip JM, Ilonen JS, Laatikainen LT, (1997) Genetic markers in early diabetic retinopathy of adolescents with type I diabetes. J Diabetes Complications 11: 203-207.
42. Gray RS, Starkey IR, Rainbow S, Kurtz AB, Abdel-Khalik A, et al. (1982) HLA antigens and other risk factors in the development of retinopathy in type 1 diabetes. Br J Ophthalmol 66: 280-285.
43. Larkins RG, Martin FI, Tait BD, (1978) HLA patterns and diabetic retinopathy. Br Med J 1: 1111.
44. Malone JI, Grizzard S, Espinoza LR, Achenbach KE, Van Cader TC, (1984) Risk factors for diabetic retinopathy in youth. Pediatrics 73: 756-761.
45. Mimura T, Funatsu H, Uchigata Y, Kitano S, Noma H, et al. (2003) Relationship between human leukocyte antigen status and proliferative diabetic retinopathy in patients with younger-onset type 1 diabetes mellitus. Am J Ophthalmol 135: 844-848.
46. Mimura T, Funatsu H, Uchigata Y, Kitano S, Shimizu E, et al. (2005) Gluatamic Acid Decarboxylase Autoantibody Prevalence and Association with HLA Genotype in Patients with Younger-Onset Type 1 Diabetes and Proliferative Diabetic Retinopathy. Ophthalmology.
47. Quiroz-Mercado H, Suarez-Licona A, Fromow-Guerra J, Lopez-Carasa G, Cardenas-Hernandez R, et al. (2002) Human lymphocyte antigen DR7 protects against proliferative retinopathy with type II diabetes mellitus. Arch Med Res 33: 123-127.
48. Rand LI, Krolewski AS, Aiello LM, Warram JH, Baker RS, et al. (1985) Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med 313: 1433-1438.
49. Sterky G, Wall S, (1986) Determinants of microangiopathy in growth-onset diabetes. With special reference to retinopathy and glycaemic control. Acta Paediatr Scand Suppl 327 pp. 1-45.
50. Janeway CA, Travers P, Walport M, Shlomchik M, (2005) Immunobiology the Immune System in Heatlh and Disease New York, New York Garland Science Publishing.
51. Agardh D, Agardh E, Landin-Olsson M, Gaur LK, Agardh CD, et al. (1998) Inverse relationship between GAD65 antibody levels and severe retinopathy in younger type 1 diabetic patients. Diabetes Res Clin Pract 40: 9-14.
52. Mimura T, Funatsu H, Uchigata Y, Kitano S, Shimizu E, et al. (2004) Development and progression of diabetic retinopathy in patients with Type 1 diabetes who are positive for GAD autoantibody. Diabet Med 21: 559-562.
53. Steffes MW, Sibley S, Jackson M, Thomas W, (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26: 832-836.
54. Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, et al. (1986) Epidemiology of diabetes mellitus in Sweden. Results of the first year of a prospective study in the population age group 15-34 years. Acta Med Scand 220: 437-445.
55. Littorin B, Sundkvist G, Schersten B, Nystrom L, Arnqvist HJ, et al. (1996) Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res Clin Pract 33: 129-133.
56. Schranz DB, Bekris L, Landin-Olsson M, Torn C, Nilang A, et al. (1998) A simple and rapid microSepharose assay for GAD65 and ICA512 autoantibodies in diabetes. Diabetes Incidence Study in Sweden (DISS). J Immunol Methods 213: 87-97.
57. Olerup O, Zetterguist H, (1993) DR "low-resolution" PCR-SSP typing-a correction and an up-date. Tissue Antigens 41: 55-56.
58. Olerup O, Zetterquist H, (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235.
59. Falorni A, Örtqvist E, Persson B, Lernmark Å, (1995) Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Methods 186: 89-99.
60. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, et al. (1996) Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933.
61. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, et al. (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85: 4619-4623.
62. Landin-Olsson M, Sundkvist G, Lernmark Å, (1987) Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30: 327-332.
63. Torn C, Landin-Olsson M, Lernmark Å, Palmer JP, Arnqvist HJ, et al. (2000) Prognostic Factors for the Course of {beta} Cell Function in Autoimmune Diabetes. J Clin Endocrinol Metab 85: 4619-4623.
64. Mueller PW, Bingley PJ, Bonifacio E, Steinberg KK, Sampson EJ, (2002) Predicting type 1 diabetes using autoantibodies: the latest results from the diabetes autoantibody standardization program. Diabetes Technol Ther 4: 397-400.
65. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, et al. (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47: 1857-1866.
66. Jeppsson JO, Jerntorp P, Almer LO, Persson R, Ekberg G, et al. (1996) Capillary blood on filter paper for determination of HbA1c by ion exchange chromatography. Diabetes Care 19: 142-145.
67. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, et al. (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110: 1677-1682.
68. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B, (2003) The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 26: 1270-1276.
69. Huber PJ, The behavior of maximum likelihood estimates under nonstandard conditions; 1967 Berkeley, CA University of California Press pp. vol 1, 221-223.
70. White H, (1980) A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 48: 817-830.
71. Jensen R, Gilliam L, Torn C, Landin-Olsson M, Palmer J, et al. (2007) Islet cell autoantibody levels after the diagnosis of young adult diabetic patients. Diabet Med 24: 1221-1228.
72. McCulloch DK, (2007) Pathogenesis and natural history of diabetic retinopathy. In: Rose BD, editors. UpToDate Waltham, MA.
73. Henricsson M, Nystrom L, Blohme G, Ostman J, Kullberg C, et al. (2003) The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 26: 349-354.
74. Erdo SL, Wolff JR, (1990) gamma-Aminobutyric acid outside the mammalian brain. J Neurochem 54: 363-372.
75. Borg H, Gottsater A, Fernlund P, Sundkvist G, (2002) A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51: 1754-1762.
76. Hoeldtke RD, Bryner KD, Hobbs GR, Horvath GG, Riggs JE, et al. (2000) Antibodies to glutamic acid decarboxylase and peripheral nerve function in type 1 diabetes. J Clin Endocrinol Metab 85: 3297-3308.
77. Rakocevic G, Raju R, Dalakas MC, (2004) Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 61: 902-904.
78. Padmos RC, Bekris L, Knijff EM, Tiemeier H, Kupka RW, et al. (2004) A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. Biol Psychiatry 56: 476-482.
79. Balme M, McAllister I, Davis WA, Davis TM, (2002) Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study. Diabet Med 19: 602-605.
80. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, et al. (1999) Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 96: 13318-13323.
81. Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, et al. (2000) Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 278: E759-768.
82. Agardh E, Bruun A, Ehinger B, Ekstrom P, van Veen T, et al. (1987) Gamma-aminobutyric acid- and glutamic acid decarboxylase-immunoreactive neurons in the retina of different vertebrates. J Comp Neurol 258: 622-630.
83. Agardh E, Ehinger B, Wu JY, (1987) GABA and GAD-like immunoreactivity in the primate retina. Histochemistry 86: 485-490.